Chicago
,
US
20 - 23 June 2025
American Diabetes Association 85th Scientific Sessions (ADA 2025)
Presentation schedule and materials
Saturday, 21 June 2025
12:30
- 13:30
CDT
816-P
POSTER
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by diabetes duration: ONWARDS 1–5
Alice YY Cheng1; Gayathri Anil2; Luis Canani3,4; Jonas Kristoffer Lindeløv5; Siri Vinther5; Chantal Mathieu6;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
822-P
POSTER
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by baseline A1C: ONWARDS 1–5
Chantal Mathieu1; Gayathri Anil2; Luis Canani3,4; Jonas Kristoffer Lindeløv5; Siri Vinther5; Alice YY Cheng6;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
819-P
POSTER
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by baseline BMI: ONWARDS 1–5
Luis Canani1,2; Gayathri Anil3; Alice YY Cheng4; Jonas Kristoffer Lindeløv5; Siri Vinther5; Chantal Mathieu6;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
815-P
POSTER
CGM-derived model-based postprandial glucose with IcoSema vs other insulin regimens: a post hoc analysis of COMBINE 1 and 3
Christophe De Block1; Malik Benamar2; Ariel Fu2; Raluca Maltesen3; Francesco Giorgino4;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
804-P
POSTER
A1C and hypoglycemia outcomes with once-weekly IcoSema vs comparators in T2D by kidney function
Linong Ji1; Malik Benamar2; Benjamin Hilligsøe Harvey3; Andrea Navarria2; Paola Ponzani4; AG Unnikrishnan5; Rosangela Rea6;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
830-P
POSTER
CGM-based outcomes in adults with T2D receiving IcoSema vs comparators: post hoc analysis of COMBINE 1 and 3
Concetta Irace1; Vanja Cejvanovic2; Jonas Hughes Larsen3; Thaís M Pagliaro Rocha2; Yasuo Terauchi4; Chantal Mathieu5;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1373-P
POSTER
Comparison of Characteristics Among Individuals with Established vs Newly Diagnosed Type 2 Diabetes During Ischemic Stroke Hospitalization – A Retrospective Cohort Study
Caichen Zhong1; Seth Emont2; Lin Xie1; Sunday Ikpe2; Zhun Cao2; Craig B. Lipkin2; Joshua Noone1; Chalak Muhammad1; Adam de Havenon3
MATERIALS AVAILABLE
Sunday, 22 June 2025
08:00
- 09:30
CDT
CT-SY42-1.5
ORAL PRESENTATION
Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials
Donna H. Ryan1; Thomas A. Lutz2; Julio Rosenstock3; W. Timothy (Tim) Garvey4; Melanie J. Davies5; Sue D. Pedersen6; Louis J. Aronne7
MATERIALS AVAILABLE
12:30
- 13:30
CDT
909-P
POSTER
Prevalence and Factors for Treatment Failure with Sodium-Glucose Co-Transporter 2 Inhibitor in US Adults with Type 2 Diabetes
Xi Tan1; Yiwen Cao1; Yan Wang2; Joanna Boland2; Mico Guevarra1; Lin Xie1; Yan Song3; Min Ji Kwak4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
838-P
POSTER
Changes in Clinical Measures in US Adults with Type 2 Diabetes and Chronic Kidney Disease Who Received Once-Weekly Semaglutide
James Amamoo1; Yan Wang2; Hongjiao Liu2; Manasvi Sundar2; Yan Song3; Lin Xie1; Sherif Mehanna1; Josh Noone1; Caroline Swift1; Matthew Weir4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2005-LB
POSTER
Changes in Clinical Measures among US Adults with Type 2 Diabetes and Chronic Kidney Disease Receiving Once-Weekly Semaglutide vs. Oral Antidiabetic Medications
James Amamoo1; Yan Wang2; Hongjiao Liu2; Manasvi Sundar2; Yan Song3; Lin Xie1; Sherif Mehanna1; Josh Noone1; Caroline Swift1; Matthew Weir4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
POSTER
Macrovascular and Microvascular Complications in Medicare Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease From 2006-2021: Incidence Stratified by Sex, Age, and Race/Ethnicity
Tyler J. Dunn1; Daniel Rotroff2; Joanna Harton3; Sonia Kim3; Xi Tan1; Josh Noone1; Lin Xie1
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1969-LB
POSTER
Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity
Nikolaj Bak1; Rachel Ga Yeon Lee1; Angela Sinn2; Søren Snitker1; Valdemar Funch Uhre1; Emily Wenande1; Janne R. Hingst1
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2002-LB
POSTER
Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial
Kirsten Dahl1; Kasper Adelborg2; Sohan Dey3; Ruben Duque do Vale2; Cassandra Key4; Søren Toubro2; Ania M. Jastreboff5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1978-LB
POSTER
Efficacy and Safety of Semaglutide 7.2 mg in Obesity and Type 2 Diabetes: The STEP UP T2D Trial
Ildiko Lingvay1; Sara J Bergenheim2; John Buse3; Paula Freitas4,5; W. Timothy Garvey6; Nina M. Harder-Lauridsen2; Julio Rosenstock7; Kushal Sahu2; Sean Wharton8,9
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1966-LB
POSTER
Efficacy and Safety of Semaglutide 7.2 mg in Obesity: The STEP UP Trial
Sean Wharton1,2; Paula Freitas3,4; Jøran Hjelmesaeth5,6; Maria Kabisch7; Kristian Kandler8; Ildiko Lingvay9; Maria De Los Angeles Quiroga Pelaez7; Julio Rosenstock10; W. Timothy Garvey11
MATERIALS AVAILABLE
12:30
- 13:30
CDT
732-P
POSTER
Real-world Impact of Oral Semaglutide Alone and vs DPP-4is on Weight, BMI and HbA1c Outcomes in Type 2 Diabetes (T2D): An Observational Study (PAUSE)
James Amamoo1; Riddhi P Doshi2; Joshua Noone1; Lin Xie1; Mico Guevarra1; Victoria Divino1†; Justin Chen2†; Aaron Asa King3
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1971-LB
POSTER
Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD: Data from the FLOW Trial
Johannes F. E. Mann1,2; Katherine R. Tuttle3,4; Richard E. Pratley5; Kenneth W. Mahaffey6; Mustafa Arici7; Nicolas Belmar8; Karen Bonefeld8; Gil Chernin9; Ricardo Correa-Rotter10; Pieter Gillard11; Samy Hadjadj12; Thomas Idorn8; Linong Ji13; Soo Kun Lim14; Martin Linder8; Roland Schmieder15; Minara Shamkhalova16; Apiradee Sriwijitkamol17; Vlado Perkovic18; Peter Rossing19
MATERIALS AVAILABLE
12:30
- 13:30
CDT
782-P
POSTER
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
Peter Rossing1,2; Morten Lindhardt2,3; Christian Klyver Tikkanen4; Jyothi Menon5; Juliette Cattin6; Barnaby Hunt6; Samuel JP Malkin6; Barrie Chubb5; Tina Damgaard4; Rikke Borg2,7
MATERIALS AVAILABLE
Monday, 23 June 2025
12:30
- 13:30
CDT
427-P
POSTER
Elevated body mass index at type 2 diabetes diagnosis is associated with increased risk of cardiovascular disease and kidney outcomes
Akshay Jain1; Peter Nørgaard Kristensen2; Rie Strøbeck Wasehuus2; Joe Hollinghurst3; Emil Nørtoft2
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1733-P
POSTER
Two-year Real-world Effectiveness of Semaglutide in Patients With Obesity or Overweight
Aleksandrina Ruseva1; Wojciech Michalak1; Anthony Fabricatore1; Bríain Ó Hartaigh1; Julia Wang1; Zhenxiang Zhao1
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1734-P
POSTER
Reduction of the 10-Year ASCVD risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care: A Real-World Study
Aleksandrina Ruseva1; Matthew E. Bassan1; Ella X. Du2; Anthony Fabricatore1; Briain O Hartaigh1; Ameur Manceur3; Wojciech Michalak1; Ramya Ramasubramanian2; Jinlin Song2; Zhenxiang Zhao1; Francisco Lopez-Jimenez4
MATERIALS AVAILABLE
13:30
- 13:45
CDT
315-OR
ORAL PRESENTATION
Effect of telemonitoring using connected devices on insulin injection adherence in people living with T2D
Thomas Kronborg1,2; Stine Hangaard1,2; Niels Væver Hartvig3; Anne Kaas3; Nikoline Nygård Knudsen3; Peter Vestergaard2,4
MATERIALS AVAILABLE
13:45
- 14:00
CDT
292-OR
ORAL PRESENTATION
Oral Semaglutide and Cardiovascular Outcomes by Baseline A1c and BMI in People with Type 2 Diabetes in the SOUL Trial
Silvio E. Inzucchi1; Rohana Abdul Ghani2; John Deanfield3; Mads D. M. Engelmann4; G. Kees Hovingh4; Ole K. Jeppesen4; Monika Kellerer5; Kabirdev Mandavya6; Johannes F. Mann7; Nikolaus Marx8; Chantal Mathieu9; Darren K. McGuire10; Viswanathan Mohan11; Sharon L. Mulvagh12; Rodica Pop-Busui13; Neil R. Poulter14; Maria Sejersten Ripa4; Gabriela Roman15; Róbinson Sánchez García16; Michael Shechter17; John B. Buse18on behalf of the SOUL Study Group
MATERIALS AVAILABLE
Keywords